Lyell Immunopharma (NASDAQ:LYEL) versus HCW Biologics (NASDAQ:HCWB) Head-To-Head Contrast

Lyell Immunopharma (NASDAQ:LYEL) and HCW Biologics (NASDAQ:HCWB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, valuation, risk and earnings.

Insider & Institutional Ownership

66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 3.0% of HCW Biologics shares are held by institutional investors. 6.2% of Lyell Immunopharma shares are held by insiders. Comparatively, 9.1% of HCW Biologics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Lyell Immunopharma and HCW Biologics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Lyell Immunopharma	-920,285.25%	-91.62%	-70.50%
HCW Biologics	-83.03%	-262.33%	-34.90%

Analyst Recommendations

This is a summary of current recommendations and price targets for Lyell Immunopharma and HCW Biologics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lyell Immunopharma	1	1	6	1	2.78
HCW Biologics	1	0	1	0	2.00

Lyell Immunopharma currently has a consensus price target of $40.86, suggesting a potential upside of 334.19%. HCW Biologics has a consensus price target of $30.00, suggesting a potential upside of 2,486.21%. Given HCW Biologics’ higher probable upside, analysts clearly believe HCW Biologics is more favorable than Lyell Immunopharma.

Risk & Volatility

Lyell Immunopharma has a beta of -0.03, suggesting that its share price is 103% less volatile than the S&P 500. Comparatively, HCW Biologics has a beta of 2.41, suggesting that its share price is 141% more volatile than the S&P 500.

Valuation & Earnings

This table compares Lyell Immunopharma and HCW Biologics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lyell Immunopharma	$27,000.00	8,540.10	-$274.45 million	($12.83)	-0.73
HCW Biologics	$6.72 million	0.39	-$7.96 million	($27.60)	-0.04

HCW Biologics has higher revenue and earnings than Lyell Immunopharma. Lyell Immunopharma is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Summary

HCW Biologics beats Lyell Immunopharma on 8 of the 15 factors compared between the two stocks.

About Lyell Immunopharma

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

About HCW Biologics

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.